Pharmafile Logo

MAKING THE FIRST YEAR MATTER

October 26, 2021 |  

*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded a ‘Communique’ award for ‘Excelling in multi-channel campaigns’ for its work with CSL Behring, alongside six further award commendations and wins  *The agency offers a ‘health first, sector second’ approach with access to sector experts with unparalleled breadth and depth of capabilities *The growth has led to more than 60 new hires globally, and senior promotions to the UK leadership team alongside the launch of Gravity.ai – a first of its kind global healthcare intelligence data platform

Mind+Matter(an Ashfield Health company, part of UDG Healthcare), a ‘global creative powerhouse in health’ is celebrating its first year of business after securing more than £4 million in new business revenue across key strategic wins that span pharma, medical devices, consumer and animal health clients.

Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind+Matter team, led by Corrina Safeio, has gone from strength to strength, drawing on the expertise of its world-class experts based globally.

New senior roles include the promotion of Ian Rayfrom Associate Creative Director to Creative Director, and Kesha Tansey to Client Director. Ian and Kesha join the UK Mind+Matter leadership team and will pay a key role in shaping the future strategy and direction of the agency.

Safeio says it’s already very clear by the raft of new business wins that the health sector needs a deeply interconnected, cross-sector response to both existing clients and new client challenges.

“It’s been a phenomenal first year for Mind+Matter and I’m extremely proud of our talented team and what we have been able to accomplish together. Creating meaningful experiences by bringing data and emotion together to drive behaviour change is at the heart of what we do, day in day out. It’s this proposition alongside our health first, sector second approach that has chimed most with clients –existing and new.”

At the heart of the Mind+Matter offer is CHANGE, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid-19).

In its first year, Mind+Matter also launched Gravity.ai a first of its kind global healthcare intelligence data platform. Gravity.ai incorporates artificial intelligence, predictive analytics, data modelling and scientific human consultancy to better understand audiences, behaviour and channel performance, ensuring clients get the best value for their investment.

Safeio adds: “Covid has shown how our individual health is also a truly global issue and personalised communications have never been more important. Matched with our deep earned, owned and paid expertise, Gravity.ai allows us to discover meaningful links between demographics, technologies, and customer behaviours and track the changing dynamics of HCP, patient and consumer communications in a rapidly shifting digital world. This powers our planning model CHANGE, along with proven behavioural science. It’s powerful stuff that delivers impactful, measurable results.”

Ben Beckley leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio and Carina Whitridge, who head up the EMEA and US regions respectively.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Interactive infographic: LATAM

An overview of the six most-commonly researched, largest pharma markets in Latin America

Immuno-oncology: The market opportunity for PD-1/PD-L1s

Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies,...

Case Study: Using ‘Journey to the Future’ projective techniques to understand evolving customer expectations

Our client was developing a portfolio of innovative treatments and was in the process of recruiting a sales force to support the promotion of this portfolio. Research was required to...

Pegasus scoops five ‘Consultancy’ wins, making 2016 a stellar year for the health comms consultancy

Pegasus, an Ashfield company, part of UDG Healthcare plc, last night scooped its fifth ‘consultancy’ award of the year at the PRCA Awards in London’s Park Lane where it secured...

Free Thinking – US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare

Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare

Pegasus crowned PR Week’s Specialist Consultancy of the Year, making a hat-trick of Consultancy wins in 2016!

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have been crowned Specialist Consultancy of the Year at this week’s prestigious PR Week Awards. The accolade tops...

Therapy Watch market snapshots

Therapy Watch is a ‘real-time’ syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed,...

Case Study: Private market opportunity for a travel vaccine

Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine:Which markets had the highest potential to...

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.